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Fluoxetine (FLX) is a selective serotonin reuptake inhibitor (SSRI). Its action is possibly through an increase in neural cell survival.
The mechanism of improved survival rate of neurons by FLXmay relate to the overexpression of some kinases such as Akt protein.
Akt1 (a serine/threonine kinase) plays a key role in the modulation of cell proliferation and survival. Our study evaluated the
effects of FLX on mesenchymal stem cell (MSC) fate and Akt1 phosphorylation levels in MSCs. Evaluation tests included reverse
transcriptase polymerase chain reaction, western blot, and immunocytochemistry assays. Nestin, MAP-2, and 𝛽-tubulin were
detected after neurogenesis as neural markers. Ten 𝜇M of FLX upregulated phosphorylation of Akt1 protein in induced hEnSC
significantly. Also FLX did increase viability of these MSCs. Continuous FLX treatment after neurogenesis elevated the survival
rate of differentiated neural cells probably by enhanced induction of Akt1 phosphorylation. This study addresses a novel role of
FLX in neurogenesis and differentiated neural cell survival that may contribute to explaining the therapeutic action of fluoxetine
in regenerative pharmacology.
1. Introduction
Recent works in stem cell biology have opened up new ways
in therapeutic strategies to replace lost cells with stem cells in
injuries. Cell therapy will be an effective strategy for treating
neurodegenerative diseases and spinal cord injuries [1]. How-
ever the important part of the successful therapy depends on
differentiation and promoting the survival of implanted cells.
The survival rate of stem cells after differentiation and trans-
plantation is important for the efficacy of cell therapy [2].
Some factors are involved in the regulation of neurogenesis
and their survival. Corticosteroids were the first hormones
found to have a neurogenesis effect [3]. Neurotransmitters
and growth factors also can affect neurogenesis [4]. Based
on the fact that fluoxetine (FLX) improves brain function,
researchers have explored the effect of antidepressants on the
neurogenesis. FLX was the first selective serotonin reuptake
inhibitor (SSRI) approved for the treatment of depression.
On the molecular basis of its clinical efficacy, FLX increases
serotonin synaptic availability [5]. Increased neurogenesis
started by antidepressants in some manner contributes to
their therapeutic effects [6].These results provide some initial
insights, but more work is needed to fully elucidate the SSRI
actions on stem cell neurogenesis.
To promote extended survival of transplanted stem cells,
we must modulate the properties of the cells. This purpose
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might be accomplished by overexpressing Akt1 protein which
is a general mediator of cell survival signal. Akt is a ser-
ine/threonine kinase that plays a key role in the modulation
of cell proliferation and survival. It is wellknown for its
antiapoptotic effects against a variety of situations including
oxidative and osmotic stress, irradiation, and ischemic shock
[7–10].
This study aimed to investigate whether fluoxetine could
induce neurogenesis in mesenchymal stem cells and to fur-
ther examine the putative role ofAkt1 and its phosphorylation
in FLX-mediated effects.
2. Materials and Methods
2.1. Isolation and Culture of Human Endometrial Stem Cells.
This study was carried out in accordance with the Tehran
University ofMedical Sciences Ethical Committee Law.There
was a consent form for each donor that is included in the
supplementary data. Here we were using human endometrial
stem cell (hEnSC) as a source ofmesenchymal stem cell. Stem
cell was obtained from 30 donors between 25 and 35 years
old in the gynecology department as described previously
[11]. Briefly, the biopsies from endometrium were dissected
and then treated with collagenase (Sigma, USA) for 45min.
Isolated cells were suspended in phosphate buffered saline
(PBS, Sigma, USA) supplemented with 10% fetal bovine
serum (FBS; Gibco, UK), 0.2mM EDTA (Sigma, USA),
100U/mL penicillin, and 0.1mg/mL streptomycin (Gibco,
UK).The cells were layered on Ficoll Paque (Sigma,USA) and
centrifuged at 400 g for 35min at 4∘C. EnSCs were retrieved
from the buffy coat layer, washed in PBS, and then kept in
DMEM/F12 medium (Gibco, UK). In the passage two, the
CD146+, CD105+, and CD90+ cells were isolated from total
cells [12] by the fluorescent analyzer cell sorter (FACS).
2.2. Mesenchymal Stem Cells Differentiation. Human EnSCs
were placed on collagen precoated plates with DMEM low-
glucose medium.The cultures were kept in a humidified 10%
CO
2
atmosphere at 37∘C for 10 days.Themedia were replaced
with freshmedia every 3 d. Stem cells that have grown to 70%
confluence were pretreated with 1𝜇M dimethyl-sulfoxide
(DMSO, Sigma, USA) and then were treated with fluoxetine
(1, 2, 5, and 10 𝜇M,Sigma,USA). Treatmentwith 1𝜇Mretinoic
acid (RA, Sigma, USA) and dH
2
O was done as positive
and negative controls in order. Also hEnSCs cultured in
FLX treated media containing 10 𝜇Mphosphatidylinositol-3-
kinase (PI3-K) inhibitor (LY294002, Promega, USA) served
as control cells to determine the Akt role. After treatment for
10 d, cells were subjected to examining the Akt1 phosphoryla-
tion bywestern blot and for specificmarkers of neural cells via
reverse transcriptase PCR and immunocytochemistry assays.
In each experiment, a nontreated group was tested.
2.3. Reverse Transcriptase PCR Analysis for Neural Specific
Markers. For collection of total RNA from treated hEnSCs,
we used an Isogen kit according to the manufacturer’s
instructions (Nippon Gene, Tokyo, Japan). RNA quantity
andpuritywere determined by spectrophotometry (Beckman
DU-65). Standard reverse transcription was performed using
the AMV kit (Takara Biomedicals, Ohtsu, Japan) with 1 𝜇g
RNA and 0.5 𝜇g oligo-dT per reaction, according to the man-
ufacturer’s instructions. Reaction mixtures included 2.5𝜇L
cDNA, 1x PCR buffer (AMS TM, Cinnagen, Iran), 200𝜇M
dNTPs, 0.5 𝜇M of each of forward and reverse primers
(Table 1), and 1U Taq DNA polymerase. Polymerase chain
reactions were performed at 94∘C for 1min, 30 cycles 94∘C
for 30 s, 55–63∘C for 30 s, and 72∘C for 30 s, and 72∘C for
10min. Amplified DNA fragments were electrophoresed on
1.5% agarose gel.Thegelswere stainedwith ethidiumbromide
(10 𝜇g/mL) and photographed on a UV transilluminator
(Uvidoc, UK).
2.4. Neural Markers Immunostaining. The hEnSCs treated
with FLX and FLX + 10 𝜇M PI3-K inhibitor (LY294002,
Promega, USA) were fixed by incubation in 9% paraformal-
dehyde for 20min and permeabilized with 0.5% Triton X-100
for 10min as described previously [1]. The cells were then
reacted with primary antibodies for Nestin (Sigma, USA),
MAP-2 (Sigma, USA), 𝛽-tubulin-III (Chemicon, USA), and
CD11b as a glial marker (Millipore, USA) at 4∘C for 12 h,
washed with PBS and reacted with the fluorescent isothio-
cyanate (FITC) conjugated secondary antibody (Sigma,USA)
at room temperature for 2 h. Finally, the cells were washed
with PBS three times, and DAPI was used for DNA staining.
2.5. Detection of Akt1 Phosphorylation via Western Blotting.
After FLX treatment, the cell lysates were collected and
protein concentration was determined by using a protein
assay kit (Bio-Rad, USA). Total cell extracts containing
equal amounts of protein in sample buffer were subjected
to WB analysis as described previously [13]. Briefly, the
samples were boiled for 5min and then separated by 12%
sodium dodecyl sulfate polyacrylamide gel electrophore-
sis (SDS-PAGE). After that, the gel was transferred onto
polyvinylidene difluoride (PVDF) membrane for blotting.
The membrane was first blocked by incubation in bovine
albumin at room temperature for 2 h and then incubated
with anti-Akt1 antibody (Cell Signaling Technology, USA)
and anti-phospho-Akt1 antibody (Cell Signaling Technology,
USA) for 2 h at room temperature, washed for 3 times
with tris buffer containing Tween-20 and incubated at room
temperature with HRP conjugated secondary antibody for
2 h. The membrane was washed 5 times with tris buffer, and
then specific bands were quantified using a ChemiImager
System (Alpha Innotech Corporation). Anti-𝛽 actin antibody
(Abcam, UK) was used as an internal control.
2.6. Viability Test (MTT) in Neural Differentiated Cells.
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide) assay is a useful colorimetric test for detection
of cell viability. MTT is for measuring the activity of cel-
lular enzymes that reduce the yellow tetrazolium dye, to
its insoluble formazan, giving a purple color. Differentiated
mesenchymal stem cells were tested for their survival time in
the presence or absence of FLX. The EnSCs were plated into
96 well enzyme linked immunosorbent assay (ELISA) plates,
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Table 1: Primers used for specific neuronal genes expression.
Target genes Primer sequences Accession number
Nestin F: 5
󸀠-GCCCTGACCACTCCAGTTTA-3󸀠 NM:051373
R: 5󸀠-GGAGTCCTGGATTTCCTTCC-3󸀠
Map-2 F: 5
󸀠-CCATTTGCAACAGGAAGACAC-3󸀠 NM:002374.3
R: 5󸀠-CAGCTCAAATGCTTTGCAACTAT-3󸀠
Β-tubulin F: 5
󸀠-ATGTACGAAGACGACGAGGAG-3󸀠 NM:BC:003021
R: 5󸀠-GTATCCCCGAAAATATAAACACA-3󸀠
𝛽-actin F: 5
󸀠-AAGAGAGGCATCCTGACCCT-3󸀠
R: 5󸀠-ACATGGCTGGGGTGTTGAAGC-3󸀠
and the differentiation process was repeated as described
previously in Section 2.2. After the differentiation for replac-
ing the culture media, FLX was added to three of the wells
and PBS was used as a negative control in three other
wells. Culture plates were incubated for one week. During
incubation (7 d), culture media were replaced with medium,
containing FLX, FLX + LY294002, and PBS. Cell viability was
assessed by MTT assay kit (Biotium, Hayward, USA). The
MTT reagent (10 𝜇L) was added to the wells and incubated
for 3 h. At the end of the incubation period, the medium was
removed and 100 𝜇L DMSO was added into each well. To
dissolve the formazan crystals, the supernatant was pipetted
several times. Absorbance was measured on an ELISA plate
reader at a wavelength of 540 nm.
2.7. Labeling Cell with 5-Bromo-20-deoxyuridine. One 𝜇M
BrdU was added to the cultures for 6 h on the 8th day of
FLX induction. The cells were observed on the 9th day of
BrdU labeling and then fixed on the 10th day of development
and stained for BrdU and Nestin with anti-BrdUmonoclonal
antibody (Sigma, St. Louis) overnight at 4∘C and labeled
with secondary antibody conjugated with Rhodamine for 120
minutes at room temperature. BrdU and Nestin positive cells
were counted in 10 microscopic fields. The percentage and
standard deviation of double stained cells among all Nestin
positive cells were calculated.
2.8. Statistical Analyses. Data shownwere expressed asmeans
± S.D. from data obtained in three independent experi-
ments. MTT and western blot results are obtained from six
independent experiments. ANOVA was used to compare
the effects of all treatments. Differences of viability within
experimental groups were determined by theMann-Whitney
test. Differences were considered statistically significant at
𝑃 ≤ 0.05.
3. Results
3.1. Human Endometrial Stem Cell Culture. Human EnSCs
analysis by FACS showed thatmore than 90%of the cells were
CD146+, CD105+, and CD90+ (Figure 1). This test confirms
the true isolation of stem cells from the lining womb. To
determine whether the hEnSCs could respond to FLX or not,
we treated the stem cells with 1–10 𝜇g serial concentrations of
FLX over a period of 10 d on collagen precoated and DMSO
pretreated plates. In this work, human EnSCs with spindle
shaped morphology were cultured (Figure 2(a)). After 10 d,
fibroblast-like cells with spindle-shapemorphology appeared
on culture dishes (Figure 2(b)). Considering the role of FLX,
we investigated its effect on the stem cell differentiation.
Dendrite and axon formation and also neurite outgrowth
that are phenotypic changes into neural fate were obvious
(Figure 2(c)), and it was comparable with retinoic acid effects
as a positive control (Figure 2(d)).
3.2. Expression of Differential Neural Genes. The in vitro study
is conducted to determine that the neurogenesis regulating
effect could be replicated in cell culture system. One week
after the treatment of hEnSCs, we examined the neural
markers by RT-PCR. RT-PCR analysis was indicative of the
expression of nestin,map-2, and 𝛽-tubulin genes as shown in
Figure 3.
3.3. Immunostaining of Neuronal Induced Specific Markers.
Fluoxetine treated and differentiatedmesenchymal stem cells
were visualized by the staining of some neuronal markers.
Immunocytochemistry was used to analyze theNestin,MAP-
2, and 𝛽-tubulin proteins. The result showed that these
proteins were detected after treatment in 10 d (Figure 4(a)).
Also a group of cells that were treated with LY294002 as
a phosphatidylinositol-3-kinase (PI3-K) inhibitor did not
express the neural markers even after 10 d treatment by FLX
(Figure 4(b)).
3.4. Overexpression of Phosphorylated Akt1. Phosphorylation
of Akt1 in FLX-treated mesenchymal stem cells as detected
by western blot was higher than non-FLX-treated stem cells.
Also LY294002 as a PI3-K inhibitor inhibited the phosphory-
lation of Akt1 significantly (Figure 5).
3.5. Viability of FLX Treated Cells. The effect of FLX on the
survival period of the differentiated stem cells was observed
directly and investigated byMTT assay. As shown in Figure 6,
FLX treatment affects the cell survival rate significantly (𝑃 <
0.05) higher than all other groups. While the retinoic acid
strongly suppressed cell survival in this assay, the suppressive
effect of FLX on differentiated stem cells was very low.
The continuance of FLX treatment extended the time and
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Figure 1: Characterization of human endometrial stem cells via fluorescent analyzer cell sorter (FACS). Human EnSCs after the second
passage were sorted and analyzed by FACS for CD105+, CD146+, and CD90+ markers.
percentage of cell viability (Figure 6). The BrdU labeled cells
were observed 24 h after labeling that showed over 90% of
hEnSCs were BrdU positive (Figure 7(a)). The amounts of
Nestin-BrdU positive cells were determined on the 10th day
in cultures. The percentage of double stained cells among all
Nestin positive cells and standard deviation were calculated
fromdata of 10microscopic fields. Cultures treatedwith BrdU
and fixed on the 10th day contained about 60%double stained
positive cells (Figure 7(b)).
4. Discussion
Differentiation of mesenchymal stem cells into a specific
lineage, their survival, and functionality are related to
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Figure 2: Morphological characteristics and differentiation of hEnSCs into neural cells. (a) Human EnSC (passage 2) in DMEM low glucose
(b), after 10 d in DMEM pretreated with DMSO (c), plus 10𝜇M of FLX and (d) 1 𝜇g/mL of retinoic acid as a positive control (magnification:
×400).
Control FLX treated
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Figure 3: Expression of differential genes. Expression of Nestin,
Map-2, and 𝛽-tubulin neuron markers was analyzed in control
culture and FLX (10𝜇M) treated and induced differentiation culture
after 10 d.
molecular regulation.Themain finding of this research is that
the fluoxetine antidepressant could induce neurogenesis in
mesenchymal stem cells and upregulate the phosphorylation
of serine/threonine kinase Akt1, and therefore it could be
a differentiation and proliferation signaling mediator in cell
therapy.
Selective serotonin reuptake inhibitors like FLX facil-
itate signaling of serotonin by inhibiting its reuptake. At
the molecular levels, FLX increases synaptic availability of
serotonin [14]. It has been shown that FLX could inhibit
or activate PI3k/Akt or ERK1/2 pathways depending on the
cell types and their function [15–17]. So it could have a dual
role in the cancer therapy and cell therapy in regenerative
medicine. For this purpose, we selected the Akt signaling to
determine its role in mesenchymal stem cell proliferation,
differentiation, and survival.
First, our in vitro study was conducted to determine the
possibility of neurogenesis by FLX in the mesenchymal stem
cell system (Figures 2(a) and 2(b)). Our results demonstrated
that hEnSCs could be induced to differentiate into neurons in
the presence of FLX (Figure 2(c)) as was seen in cells treated
with retinoic acid (Figure 2(d)). High concentrations of FLX
have nonserotoninergic effects on cells [5]. Nonserotonin-
ergic targets of fluoxetine that mediate its other effects are
likely to have a lower binding affinity or lower availability for
FLX. Inhibition of cytochrome P450 is known to be due to a
nonserotoninergic effect of FLX [18]. Lee et al. (2008) showed
that liver cytochrome P450-dependent ROS formation is
responsible for cyclin-A downregulation and inhibition of
6 BioMed Research International
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Figure 4: Immunostaining of hEnSCs differential markers. Expression of neuron markers including Nestin, MAP-2 and 𝛽-tubulin was
analyzed in FLX induced differentiation after 10 d. The expression of CD11b as a glial marker was not obvious. The size bar is 10𝜇m (a).
Immunostaining of LY294002 treated hEnSCs after culture in FLX supplemented medium. There is not an expression of neuron markers in
FLX induced differentiation after 10 d (b).
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Figure 5: Western blot results after treatment of hEnSC with 10 𝜇M
fluoxetine after 10 d. Protein samples (100𝜇g) were loaded onto
SDS PAGE gels and transferred to PVDF membranes. The induced
EnSCs produced an increase expression of phosphorylated Akt1
protein. 𝛽-Actin was used as an internal control.
neural progenitor cell proliferation [19] so inhibition of
cytochrome P450 may inhibit cyclin-A downregulation and
restoring cyclin-A reverse inhibition of neural progenitor
cell proliferation. However, this induction did not occur in
the brain and suggested a tissue-specific response [20]. It
has been demonstrated that the SSRIs interact with the eag
voltage-gated K
1
channel [21], and voltage-gated potassium
channels play a functional role in the development of human
neural progenitor cells and differentiation of neurons [22].
Also studies by deOliveira and colleagues in 2012 showed that
eag potassium channel expression in the rat hippocampus has
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Figure 6: MTT shows EnSCs differentiated neural cell viability rate
in the presence of FLX, FLX + LY294002, LY294002, and retinoic
acid after one week (𝑃 ≤ 0.05). The numbers from the left side are
as follows: (1) 1 𝜇M FLX, (2) 5 𝜇M FLX, (3) 10 𝜇M FLX, (4) 10 𝜇M
FLX + 10𝜇M LY294002, (5) 10𝜇M LY294002, (6) 1𝜇M retinoic
acid, (7) neural differentiated cells without FLX supplement, and (8)
undifferentiated mesenchymal stem cells.
been associated with neural cell survival and transient brain
ischemia [23].
In our experiment, fluoxetine-induced hEnSCs displayed
neuronal morphology with axon formation and neurite
outgrowth and expressed Nestin and other neuronal specific
molecular markers by the reverse transcriptase polymerase
chain reaction (Figure 3) and immunocytochemistry (Fig-
ure 4(a)) assays. EnSCs cultured in serum-free DMEM/F12
medium could not differentiate or even proliferated con-
stantly. These findings indicate FLX-induced EnSCs may
provide a stem-cell-based way to generate neuronal cells for
the treatment of neurodegenerative diseases. This finding
could determine that the endometrial stem cells express sero-
tonin receptors. In neuropharmacology, it may be beneficial
to study the effect of the different antidepressants on the
neurogenesis since this provides insights into the regulation
of stem cell proliferation.
Regeneration of neurons that undergo cell death soon
after injury is the main goal of all cell-based therapies. From
the point that neurogenesis has the capacity to enhance
brain repair and/or spinal cord repair after ischemia and/or
trauma by replacement of dead cells or seriously injured cells
FLX neurogenesis could lead to recovery of these cells. FLX
would appear to be a candidate as a neurogenesis factor. Our
experiment showed that the hEnSCs expressed neural cell
markers after FLX treatment, but there was no expression of
CD11b marker that is a specific glial marker (Figure 4(a)).
This is an important point because glial scar formation that
occurs following CNS injuries is an important obstacle of
neuroregeneration. FLX could introduce a regenerative prod-
uct in neuronal injuries and find its position in regenerative
pharmacology.
Many groups have examined the potential of neu-
ron replacement from embryonic stem cells [24], induced
pluripotent stem cells (iPS) [25, 26], and cord blood derived
stem cells. Endometrial stem cells have demonstrated supe-
rior potential. They expand rapidly and they have fewer
technical and ethical problems so they have great potential
as therapeutic agents and autologous grafts [2]. Our team
has previously shown that the endometrial stem cells could
be differentiated successfully into other lineages of cells
especially neural cells [1, 11]. It represents a progress in the
development of a new source of neurons.
We further confirmed the protective mechanisms of Akt1
phosphorylation as a survival signaling that introduces this
pathway as a potential target for stem cell survival after dif-
ferentiation of mesenchymal stem cells (Figure 6). PI3k/Akt
is the important cell survival pathways and phosphorylation
of Akt mediates anti-apoptosis in many kinds of cells [27]. In
2003, Kim et al. have shown that the Akt activation results in
phosphorylation and then inactivation of the pro-apoptotic
protein glycogen synthase kinase 3 (GSK3b), thus extending
the cell survival period [28]. In support of the role of Akt1
phosphorylation, we found that the PI3K inhibitor LY294002
in the concentration of 10 𝜇M decreased the FLX mediated
Akt phosphorylation (Figure 5), differentiation (Figure 4(b)),
and the viability of neuronal differentiated cells (Figure 6).
This suggests a key role for activating Akt1 in the protection
of mesenchymal stem cell from the precocious death. Also
we have labeled the hEnSCs with BrdU to obtain more exact
cell proliferation rate (Figure 7(a)). The FLX treated stem
cells that were labeled with BrdU showed double-staining for
both BrdU and Nestin on the 10th day. Cells acquiring Nestin
positive phenotype seemed to go through cell cycles enough
to dilute the BrdU label to the non-detectable levels. In our
experiment, BrdUwas added on the 8th day of induction, and
about half of nestin positive cells carried BrdU-label on the
10th day (Figure 7(b)). In cultures that FLX was absent about
70% of Nestin positive cells carried BrdU-label.
In 2006, Frebel and Wiese confirmed the neuronal sur-
vival and differentiation implicated PI3-K/AKT in synaptic
plasticity, learning, and memory in the mammalian brain
[29].
Although this finding supports the neurogenesis role of
SSRIs, it has been suggested that excessive neurogenesis is
not beneficial and could result in inappropriate migration
into existing neural networks. Scharfman and Hen believe
that this manner could cause some pathological conditions
as epilepsy [30], but previously Rush et al. reporting that
SSRIs could lose their effect after long-term use [31]. This
has been called relapse during maintenance treatment. A
possible mechanism underlying this effect is the weakness
of neurogenesis because of excessive stimulation. So it is
possible that long-term SSRI therapy might affect PI3/Akt
pathway and its activation that leads to cognitive functions
by disrupting the normal regulation of neurogenesis.
5. Conclusion
In conclusion our data argue with fluoxetine effect on
mesenchymal stem cell neurogenesis and its role in the
phosphorylation of Akt1 in the differentiated cells to increase
the survival rate of differentiated cells.
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(a)
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(b)
Figure 7: Endometrial stem cells labeled by BrdU (a). Cultures were treated with FLX and labeled with BrdU. They were then stained with
antibodies against BrdU and nestin, followed by either rhodamine- (for BrdU, red) or FITC- (nestin, green) labeled secondary antibodies (b).
Data are representative of 3 independent experiments.
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